Clinical Study on the Combined Detection of Plasma GNB4 and Riplet Gene Methylation for Monitoring Primary Liver Cancer Recurrence

What this Trial Is About

Researchers are evaluating a combined methylation detection kit for GNB4 and Riplet genes using a fluorescent PCR method to monitor recurrence of primary liver cancer. This observational trial compares the new methylation assay with the clinical reference standard, which is based on physicians' comprehensive diagnoses following clinical guidelines. The study aims to assess how well this blood test detects cancer returning after treatments like hepatectomy, liver transplantation, ablation, or transarterial chemoembolization (TACE). The study involves patients who have been treated for primary liver cancer with one or more of these methods and are undergoing follow-up testing. At various times after treatment, blood samples are tested for methylation of the GNB4 and Riplet genes to detect cancer recurrence. This approach is compared to standard clinical evaluations to validate its effectiveness as a monitoring tool. Participants will be monitored for about one year through regular follow-ups to measure the sensitivity and specificity of the methylation detection test. Researchers will assess how accurately the test identifies recurrence compared to the clinical diagnosis. The study focuses on gathering data on the test's clinical performance in real-world patient monitoring scenarios after primary liver cancer treatment.

cfDNA Methylation for Liver Cancer Recurrence Detection